


Rejuvenate Your Unique
Microbiome With Science

G-NiB Immunity+

微生態配方 免疫+

- A Microbiome Immunity Product Developed by CUHK
- This unique formula based on the world's FIRST study of the Gut Microbiome of COVID-19 patients with demonstrated clinical benefits²⁻⁶
- Patented microencapsulation technology from Italy. Ensuring sufficient good live bacteria reach your intestine and a long shelf-life.
- Formula Customized for Asian





Gut Dysbiosis Impaired Immunity¹

- Over 100 trillion of microbes live inside our body (both beneficial and pathogenic microbes), regulating our immunity. These microbes build up our gut microbiome.
- The imbalance of the beneficial and pathogenic microbes (dysbiosis) contributes to our susceptibility to infections including COVID-19 infections.

Scientific Advancement


Using metagenomics sequencing and machine learning, The Centre for Gut Microbiota Research of The Chinese University of Hong Kong is the FIRST in the world to prove² that:

1. **Severe gut dysbiosis** exists in COVID-19 patients - Commensal symbionts were missing, pathogens increased.
2. The severity of disease symptoms were **negatively correlated with specific good bacteria**, and positively correlated with pathogenic bacteria.
3. **Specific bifidobacteria formula (PIM01)** may effectively increase these important good bacteria.



The Benefit of the Microbiome Precision Formula

The benefit is NOT limited to COVID-19 patients. Using metagenomic sequencing, the study from the Chinese University of Hong Kong demonstrated that **almost 40% of the healthy population has imbalanced gut microbiota** (marker of impaired immunity) comparable to COVID-19 patients. ⁶



Formula Developed based on the world's first microbiome study on COVID-19 patients (Patented microencapsulation technology from Italy)


Clinical benefits demonstrated in COVID-19 hospitalised patients⁷

1. Complete Symptom Resolution

100% of the patients on active arm achieved complete symptoms[#] resolution by week 2.

* (Compare 1st week 64.0% vs 10.7% ; $p < 0.0001$; Compare 2nd week 100% vs 52% ; $p < 0.0001$)

[#] Symptoms include: fever, loss of taste/ smell, diarrhea, cough, sputum, sore throat, runny nose and shortness of breath




2. Neutralizing Antibody (in blood)

For patients who received CUHK formula, compared with those who did not receive:

- 88% developed antibody within 16 days vs. 64%;
- 4% never had antibody positivity vs. 28.4% in the control arm.

* (At Day 16: 88% vs 64% ; $p < 0.025$)



* A statistically significant test result ($P \leq 0.05$). $0.05 > p > 0.01$: there is strong evidence to infer that the alternative hypothesis is true. For $0.01 > p > 0.001$, the test is highly significant.

G-NiiB® Immunity+

One sachet daily. Sprinkle in water, non-fizzy or non-alcoholic drinks, or food (below 45°C) Can be taken at any time of the day but best consumed with a meal and suitable for recovery of chronic disease patients.



G-NiiB Specific good bacteria strains were custom-selected to potentially enhance immunity.

ISO
9001

ISO
14001

ISO
22000

G-NiiB® is a biotechnology spinout from The Chinese University of Hong Kong founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science and capitalize on an exclusive Asian database to tackle a myriad of diseases including COVID-19, colorectal cancer, obesity, eczema, and autism.

References:

1. Levy, M., Kolodziejczyk, A., Thaïss, C. et al. Dysbiosis and the immune system. *Nat Rev Immunol* **17**, 219–232 (2017).
2. Zuo T, Liu Q, Zhang F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. *Gut* 2020.
3. Zuo T, Zhan H, Zhang F, et al. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. *Gastroenterology* 2020.
4. Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. *Gastroenterology* 2020; **159**(3): 944-55.e8.
5. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. *Lancet Gastroenterol Hepatol* 2020; **5**(7): 644-5.
6. Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: more than meets the eye. *Gut* 2020; **69**(6): 973-4.
7. Data on file.



GenieBiome Limited

Tel : (852) 3960 7648

www.g-niib.com



G-NiiB®
MicroBiome Precision, GenieBiome Ltd.